Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.

21 Vericiguat reduced the risk of the primary outcome in all pre‐specified subgroups, without evidence of treatment heterogeneity; however, analysis of the continuous association between time since index event and treatment effect showed a trend towards increased benefit of vericiguat with longer time since index event.

also in 53,322 other papers

7 , 8 Safety A possible trend for increased incidence of the primary outcome was observed in the vericiguat group relative to placebo.

also in 1,410 other papers

Although the potential for risk of adverse outcomes with vericiguat in patients with the highest baseline levels of NT‐proBNP cannot be excluded based on these data, the HR for Q4 did not reach statistical significance, despite analyses not being corrected for multiplicity.

also in 111,027 other papers